Table 3

Maternal serum angiogenic factors levels at four time points during pregnancy by maternal blood pressure at 11–14 weeks in the NORA cohort

Angiogenic factorsTime pointsNormal BPElevated BPHypertension (stage 1 and stage 2)
NMean (95% CI)*NMean (95% CI) *P value†NMean (95% CI)*P value‡
sFlt-1 (pg/mL)11–14 weeks7461585 (1549 to 1622)981722 (1585 to 1862)0.096751758 (1585 to 1950)0.079
18–22 weeks7451698 (1660 to 1778)981738 (1585 to 1950)0.824751905 (1698 to 2138)0.139
28–32 weeks7301660 (1585 to 1698)921698 (1549 to 1862)0.868702042 (1820 to 2291)0.001
≥34 weeks6592570 (2512 to 2692)822818 (2570 to 3162)0.201573311 (2951 to 3802)0.000
PlGF (pg/mL)11–14 weeks74637 (36 to 38)9835 (32 to 38)0.2437535 (32 to 39)0.593
18–22 weeks745269 (257 to 275)98245 (224 to 269)0.26175245 (219 to 275)0.364
28–32 weeks730617 (589 to 646)92575 (501 to 676)0.71870537 (457 to 631)0.270
≥34 weeks659380 (355 to 398)82324 (269 to 380)0.17857339 (275 to 427)0.585
sFlt-1/PlGF ratio11–14 weeks74642.7 (40.7 to 44.7)9850.1 (44.7 to 55.0)0.0137550.1 (43.7 to 56.2)0.042
18–22 weeks7456.5 (6.2 to 6.8)987.1 (6.3 to 7.9)0.201757.8 (6.8 to 8.9)0.027
28–32 weeks7302.7 (2.5 to 2.9)922.9 (2.5 to 3.5)0.643703.8 (3.1 to 4.6)0.005
≥34 weeks6596.9 (6.3 to 7.4)828.9 (6.9 to 11.2)0.100579.8 (7.4 to 13.2)0.044
  • *Means (95% CI) were adjusted for maternal race, smoking during pregnancy, maternal body mass index at blood test and gestational weeks at blood test from models with logarithm-transformed serum angiogenic factors levels as outcomes; presented as geometric means.

  • †Statistically significant difference between normal BP and elevated BP groups.

  • ‡Statistically significant difference between normal BP and hypertension group.

  • BP, blood pressure; PlGF, placental growth factor; sFlt-1, soluble fms-like tyrosine kinase 1.